Studying coagulation specific for COVID-19 using Blood-vessel-on-chip technology.
Recruiting
- Conditions
- COVID-19
- Registration Number
- NL-OMON27363
- Lead Sponsor
- ZonMw
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
Age of 18 years or older
- A suspected SARS-CoV-2 virus infection
- Need for oxygen supplementation
- CRP level > 50 mg/L
- D-dimer level > 0.5 mg/L
- Ability to provide written informed consent
Exclusion Criteria
- History of venous thromboembolism
- Use of anticoagulant therapy at inclusion
- Known hereditary or acquired thrombophilia
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of endothelial surface in the blood-vessel-on-chip model that is covered by platelets and fibirn (clotting) upon treatment with COVID-19 patient plasma. Coverage in the blood-vessel-on-chip will be measured by fluorescence microscopy.
- Secondary Outcome Measures
Name Time Method Several measurements in the patient plasma:<br>- d-dimer level<br>- thrombin-antithrombin complexes (TAT)<br>- cytokine levels ((IL-1ß, IL-6, and TNF-a)<br>- Markers of neutrophil extracellular traps (NETs) using ELISA:<br>a) Myeloperoxidase (MPO)/DNA<br>b) Citrullinated histone H3<br>- Tissue factor (TF) expressing extracellular vesicles as measured by a TF-dependent factor Xa activity assay.